학술논문
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in patients with non–small cell lung cancer and is reversed by STAT3 knockdown
Document Type
Article
Author
Pore, N.; Wu, S.; Standifer, N.; Jure-Kunkel, M.; de los Reyes, M.; Shrestha, Y.; Halpin, R.; Rothstein, R.; Mulgrew, K.; Blackmore, S.; Martin, P.; Meekin, J.; Herbst, R.; Gupta, A.; Abdullah, S.E.; Raja, R.; Frigault, M.M.; Barrett, J.C.; Dennis, P.A.; Ascierto, M.L.; Oberst, M.D.; Griffin, M.; Proia, T.A.; Bisha, I.; Miragaia, R.J.
Source
In: Cancer Discovery . (Cancer Discovery, November 2021, 11(11):2828-2845)
Subject
Language
English
ISSN
21598290
21598274
21598274